Expert Interview
Discussing Pfizer's Phase 3 EV-303 Study of PADCEV Plus KEYTRUDA in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer Patients
Ticker(s): PFE, MRK, ALPMFInstitution: Moffitt
- Genitourinary Oncologist and Interim Vice Chair at Moffitt, Clinical research director of Moffitt Cancer center's geniourinary program.
- Manages 350 patients with prostate cancer.
- Primary Research interests is integrating tumor evolution dynamics into the treatment of advanced prostate cancer, and has been PI and co-investigator in >50 clinical studies since 2010.
Describe your background and practice setting
Added By: max_adminHow many patients with bladder cancer do you currently manage?
Added By: max_adminCan you describe the standard of care for bladder cancer?
Added By: max_adminWhere would this combination therapy fit into your treatment algorithm for bladder cancer?
Added By: max_adminRate your excitement for this combination therapy on a scale of 1-10
Added By: max_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
